{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic7gtiizn3rn275bsa2rmjchntmydkt5ahpd2avgbbieu77qkccrq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mnqkcqi4k7m2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie2s6d4o7a7pweoll5nhjzvofh2trkcrbssvcyrit5tztunbmmghi"
    },
    "mimeType": "image/jpeg",
    "size": 141330
  },
  "path": "/2026/06/07/competition-obesity-drugs-clinical-blind-spots-and-more-ada/?utm_campaign=rss",
  "publishedAt": "2026-06-07T20:59:21.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Newsletters",
    "diabetes",
    "Obesity",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.",
  "title": "STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA",
  "updatedAt": "2026-06-07T21:03:57.000Z"
}